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Compared to sites in protein-coding sequences many more targets undergoing
adenosine to inosine (A-to-I) RNA editing were discovered in non-coding regions
of human cerebral transcripts, particularly in genetic transposable elements called
retrotransposons. We review here the interaction mechanisms of RNA editing and
retrotransposons and their impact on normal function and human neurological diseases.
Exemplarily, A-to-I editing of retrotransposons embedded in protein-coding mRNAs can
contribute to protein abundance and function via circular RNA formation, alternative
splicing, and exonization or silencing of retrotransposons. Interactions leading to disease
are not very well understood. We describe human diseases with involvement of the
central nervous system including inborn errors of metabolism, neurodevelopmental
disorders, neuroinflammatory and neurodegenerative and paroxysmal diseases, in which
retrotransposons (Alu and/or L1 elements) appear to be causally involved in genetic
rearrangements. Sole binding of single-stranded retrotransposon transcripts by RNA
editing enzymes rather than enzymatic deamination may have a homeostatic effect
on retrotransposon turnover. We also review evidence in support of the emerging
pathophysiological function of A-to-I editing of retrotransposons in inflammation and
its implication for different neurological diseases including amyotrophic lateral sclerosis,
frontotemporal dementia, Alzheimer’s and Parkinson’s disease, and epilepsy.
Keywords: Alu element, L1 retrotransposon, A-to-I editing, neuroinflammation, genetic rearrangement,
frontotemporal dementia, ALS, epilepsy
INTRODUCTION
The complexity of humans must be due to more than the number of their genes,
because a dichotomy exists between the functional complexity of some organs, such as the
brain, and the number of genes in humans compared to other organisms. The molecular
mechanisms of functional complexity are mannifold. It was progressively realized in recent
years that epigenetic regulation, alternative splicing, post-transcriptional and -translational
modifications, and in addition a somatic mosaicism of DNA, not only in protein-coding
sequences but also in the large genome regions that do not code for proteins and
contain amongst others regulatory functions, contribute to this complexity. One of these
post-transcriptional site-specific modifications, RNA editing, enzymatically modifies specific
nucleotides and changes one nucleotide into another. A set of RNA editing enzymes
are adenosine deaminases that act on RNA (ADAR), which recognize adenosines present
in double-stranded RNA (dsRNA) regions and catalyze the deamination of adenosine
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to inosine (A-to-I editing). Inosine in protein-coding transcripts
is read as guanosine by the cellular translation machinery.
Examples of transcripts edited by ADAR are mRNAs encoding
glutamate receptors, serotonin receptors, and potassium
channels in the central nervous system (CNS) (Rosenthal and
Seeburg, 2012; Meier et al., 2016). Adenosines are not only
deaminated in protein-coding parts, but in fact in the majority
of cases in non-coding regions of sequences. The protein-coding
part of the genome contains an estimated RNA editing to
significant extent (>20%) of∼80 genes (Nishikura, 2016) (which
might correspond to 100–150 editing sites, annotation by this
review’s authors), while the total number of A-to-I editing sites
identified to date within the Genotype-Tissue Expression (GTEx)
project are 2’802’751 with an estimated higher true positive rate
(Supplementary Note 1 in Tan et al., 2017). Most editing sites
reside in non-coding regions, and particularly within sequences
called transposons via RNA intermediates (retrotransposons).
Due to the prevalence of A-to-I editing in retrotransposons, and
the strong effort so far made to elucidate the physiological and
pathophysiological roles of retrotransposons regulated by RNA
editing, it is timely and important to review current knowledge
of these mechanisms from the point of view of neurology.
Alterations in non-coding regions of the genome in the affected
organs may explain low genotype-phenotype correlation (Erwin
et al., 2016), and this review will focus on the human CNS by
beginning with an introduction on transposable elements (TE or
transposons) and the subset of retrotransposons that has as yet
been described to be related to A-to-I editing and ADARs.
Transposons are frequent and make up about half of the
human genome (44%; Mills et al., 2007). They can be classified
into class I retrotransposons and class II DNA transposons upon
their structural characteristics and mechanism of transposition
(Cordaux and Batzer, 2009; Erwin et al., 2014; Kazazian, 2017).
Class I retrotransposons, and in particular non-long terminal
repeat (LTR) retrotransposons are regulated by RNA editing.
Some remarkable characteristics should briefly be emphasized
here: First, the DNA sequence of non-LTR retrotransposons
contains a poly(A) tail at its 3′end with up to 60 nucleotides
in length (Kazazian et al., 1988). Second, retrotransposons
are transcribed by RNA polymerase II or III as non-coding
transcripts with a poly(A)-tail and exported to the cytoplasm, or
they are embedded in untranslated regions of RNA polymerase
II generated mRNAs. As introns are spliced out prior to
cytoplasmic export, retrotransposons are found in 5′UTRs and
3′UTRs of mRNAs. Lack of long terminal repeats, protein-coding
capacity, and size further determine non-LTR retrotransposon
classification. The first group consists of long interspersed
nuclear (genome) elements (LINE). One type, LINE-1 or L1,
has a full length of about 6 kb and with 500,000–700,000 copies
constitutes ∼15–17% of the human genome (Sela et al., 2007;
Beck et al., 2010). Human-specific L1 (L1Hs) represent the
only known autonomous retrotransposon family with ∼80–
100 active L1Hs elements per human individual (Brouha
et al., 2003). Most L1 have lost their ability to retranspose
probably due to accumulated mutations/fragmentation, DNA
promoter methylation and heterochromatin formation, and
ADAR1-dependent restriction through binding the basal L1-
ribonucleoprotein (RNP) complex rather than through its
editing activity (Orecchini et al., 2017a). Active L1 elements
are transcribed from an internal Pol II promoter in the 5′UTR
and contain two non-overlapping open reading frames ORF1
and ORF2. The latter encodes a protein with endonuclease
and reverse transcriptase activities. It is generally accepted that
L1 endonuclease introduces a nick at the consensus site 3′-
AA/TTTT-5′ by cleaving at the bottom strand, which allows the
T’s at the 3′ terminus of the nick to prime reverse transcription
from the poly(A) end of a L1 transcript.
The second group consists of short interspersed nuclear
elements (SINE). Alu elements are the most prevalent non-
LTR retrotransposon with >1 million copies in the human
genome (Lander et al., 2001). The typical full-length Alu element
is 300 bp, depending on the length of the 3′ oligo d(A)-
rich tail. Alu elements are either embedded in protein-coding
mRNAs or transcribed from an internal RNA polymerase III
(Pol III) promoter into single-stranded RNAs (Shen et al.,
1997). Alu elements are non-autonomous and depend on
the retrotransposition molecular machinery provided by L1
elements (Dewannieux et al., 2003). Major active subfamilies
responsible for novel retrotransposon insertions are AluYa5/8
and AluYb8/9. Over 90% of all A-to-I editing occurs in Alu
elements (Athanasiadis et al., 2004; Levanon et al., 2004), and
preferentially in those elements, which can form intramolecular
double-stranded RNA structures. Compared to the number of
editing events in Alu elements, A-to-I editing is rather low in L1
(<5%) (Athanasiadis et al., 2004; Chung et al., 2018).
A high density of genes, elevated GC-content, strong gene
expression and inverse intron length positively correlated with
high SINE density and inverse (i.e., low) LINE density (Versteeg
et al., 2003). Active retrotransposons were proposed to contribute
to a somatic mosaic and subsequently to phenotypic variation
in health and disease of the brain (Evrony et al., 2012; Upton
et al., 2015; Erwin et al., 2016). Recent work showed that novel
somatic L1 insertions occurred at a rate of ∼0.58–1 events per
cell in both glia and neurons from human hippocampus and
frontal cortex and affect at least 36% of the cells in the healthy
adult brain (Erwin et al., 2016). The same work also showed
that fixed L1 sequences in the genome may generate somatic
copy number variants (CNV) in the brain via L1 endonuclease
upregulation during neuronal differentiation. This observation
corresponds well with previous work from the same laboratory,
showing that 13–41% of cells from frontal cortex of healthy
deceased human beings harbored at least 1 new CNV between
500 kb −1Mb in size, with deletions being 2x more frequent
than insertions (McConnell et al., 2013). The novel somatic
insertion rate of Alu elements in the adult human brain is
unknown. Neuronal retrotransposition may affect memorization
(Richardson et al., 2014), which was convincingly demonstrated
in case of olfactory memory formation in Drosophila (Perrat
et al., 2013). In humans, a retrotransposition and DNA editing-
dependent process of memory encoding and storage was
previously suggested but not proven yet (Mehler and Mattick,
2007; Mehler, 2008).
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DATA BASE RESEARCH
A systematic review of primary and secondary literature was
performed here to study and discuss A-to-I editing and
retrotransposons, their functions and interactions in the human
CNS in physiological conditions and disease. PubMed was
searched using the keywords “RNA editing” or “A-to-I editing”
together with “review”, “human brain”, “micro RNA”, “piwi
RNA”, “(endo-)siRNA”, “gene expression”, and “3′-UTR.” “5′-
UTR”, “intron” that cover non-coding pre-mRNA structures.
Further search terms were “ADAR”, “ADAR, brain”, “DNA
editing, ADAR”, and “ADAR, disease”. Furthermore, PubMed
was searched using keywords “retrotransposon” or “LINE” or
“SINE” or “Alu” in combination with “incidence”, “review”,
“human brain”, “health”, “disease”, “RNA editing”, “A-to-I
editing”, “ADAR”, “ADAR1”, “ADAR2”, “APOBEC”, “(endo-
)siRNA”, “brain tumor”, extracerebral cancers (such as lung
and colorectal cancer), “epilepsy”, and “TDP-43”, Literature
search for known mechanistic interactions of RNA editing
with retrotransposons was performed using the keywords
“RNA editing”, “A-to-I editing”, “retrotransposon”, “Alu”,
“L1” together with “translational efficacy”, “gene expression”,
“gene expression, brain”, “exonization”, “exon evolution”,
“backsplicing”, “silencing”, and “circular RNA”. The investigation
of potential immunogenicity of deficiently edited inverted-
repeat Alu elements in 3′-UTR of mRNAs was done in
the context of above-mentioned keywords together with “3′-
UTR”, “inflammation”, “immunogenicity”, “immune system”,
“inflammasome”. Physiological functions of retrotransposons
and RNA editing in the CNS were investigated by searching
the PubMed database using keywords “brain development”,
“cognition”, “learning and memory”, “memory”, “neurogenesis”,
and “intelligence”. Pathophysiological functions of RNA editing
and transposable elements were investigated for all the diseases
listed in Table 1 and Supplementary Table 1, together with the
keywords “Alu”, “RNA editing”, and “ADAR”. The mechanisms
of copy number variants (CNV) were also addressed.
RETROTRANSPOSONS AND RNA EDITING
IN NORMAL BRAIN FUNCTION
Genomic deletions with transposable element (TE) involvement
have been identified, which presumedly take place in the genome
of neural progenitor cells (Erwin et al., 2016). Actually, L1
retrotransposition has already been demonstrated in neural
progenitor cells (Coufal et al., 2009), suggesting that it can
occur during adult neurogenesis in the hippocampus and
subventricular zone. It remains however to be clarified, whether
retrotransposition of L1 and Alu elements can occur in
postmitotic neurons and glia and contributes in this way to
phenotypic diversity.
A-to-I editing levels at protein-coding sites and repetitive
(typically non-coding) sites were overall comparable in various
human tissues (including the brain) of >500 individuals from
the GTEx project. Regarding editing in coding sites, cells that
make up arteries had the highest rates, while muscle cells showed
the lowest editing rates. Editing in repetitive sites was highest in
arteries and cerebellum, while muscle again showed the lowest
editing rates (Tan et al., 2017). In the following subsections,
interactions between retrotransposons and A-to-I editing at
the DNA, pre-mRNA, and mRNA levels will be reviewed and
additionally revealed whether such mechanisms have already
been demonstrated for human brain cells.
At the DNA Level
In the Drosophila nervous system, drosophila ADAR (dADAR)
can bind to a chromosomal locus containing a gene that carries
a transposon with tandem repeats, called Hoppel element, in one
of its introns (Savva et al., 2013). A long dsRNA is generated from
this transposon that can form perfectly matched double-stranded
RNA, if not edited by dADAR. Deficient or missing A-to-I editing
of the Hoppel transposon can initiate silencing of other genes and
transposons in trans. A similar mechanism of gene regulation by
editing of single-stranded TE transcripts has not been reported in
mammalian cells.
At the Pre-mRNA Level
66% of Alu elements and 58% of L1 are located in introns
of the human transcriptome (Sela et al., 2007). Over 25% of
protein-coding human mRNAs contained retrotransposons in
their 3′UTR, ∼6% carried Alu elements, and 5% L1 (Faulkner
et al., 2009).
Non-LTR retrotransposons were proposed to contribute to
the regulation of transcriptional efficiency/protein abundance
by their ability to form double-stranded (ds) RNA structures.
Through a mechanism called backsplicing, circular RNAs
(circRNA) are generated from pre-mRNAs that contain
complementary Alu elements in inverted orientation in introns
flanking exons (Figure 1A). A-to-I RNA editing may prevent
perfect dsRNA formation of inverted Alu elements and thus
suppress backsplicing. Up to 15% of actively transcribed
genes generate circRNAs and some genes seem to produce 10
times more circular than linear RNA. CircRNAs cannot be
exported into the cytoplasm and thus reduce respective gene
expression (Ivanov et al., 2015; Wilusz, 2015). CircRNAs are
highly abundant in the human brain. A catalog of neuronal
circRNAs was generated using human data from the ENCODE
project and involving neurons that were differentiated from
neuroblastoma cell lines. CircRNAs were indeed shown to be
upregulated during neuronal differentiation and after ADAR1
siRNA knockdown in neuroblastoma cells (Rybak-Wolf et al.,
2015).
A-to-I editing of intronic Alu elements may also lead to the
generation of new splice donor (AU edited to IU = GU) and
acceptor (AA edited to AI = AG) sites and trigger alternative
splicing and integration ofAlu elements into exons that can result
in novel gene functions (keyword “exonization,” Figure 1B)
(Lev-Maor et al., 2007; Möller-Krull et al., 2008; Nishikura,
2016). A well-known example is auto-editing of the human
ADARB1 (ADAR2) gene transcript by its protein, in which
intronic AA dinucleotides turn into a functional AG 3′ splice
site and alternative splicing with Alu exonization (into exon
8) creates a 2-fold difference of this gene product’s editing
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TABLE 1 | Neurological diseases with primary genetic and/or neurodegenerative origin.
Disease Transposable elements (human data) RNA editing (human data) Disease genes
Friedreich ataxia Expanded GAA triplet repeat in central Alu
linker located in FXN intron 1 with allelic
suppression
Not known FXN (9q)
Ataxia teleangiectasia Alu-mediated exonization in ATM intron 20
(Pagani et al., 2002); increased genomic L1
copy number in hippocampi from ataxia
teleangiectasia patients (Coufal et al., 2011)
Not known ATM (11q)
ALS type 12 5 patients with different types of Alu-mediated
OPTN exon deletions (Maruyama et al., 2010;
Iida et al., 2012)
Deficient GRIA2 Q/R editing in spinal motor
neurons (Kawahara et al., 2004); Deficient
GRIA2 Q/R editing suggested to contribute to
the generation of TDP-43 positive cytoplasmic
inclusion bodies (Yamashita et al., 2017)
OPTN (10p)
See OMIM for further ALS
candidate genes
Frontotemporal dementia (FTD) Unproven Alu-mediated deletion of OPTN
exons 13–15 (Pottier et al., 2015)
Not known OPTN (10p),
MAPT, PSEN1, GRN,
TARDBP, and others
ALS-FTD See ALS and FTD C9ORF72 (9p)
Hereditary spastic paraplegia Alu-mediated rearrangement of SPAST in ∼60
patients (Boone et al., 2011, 2014; Jahic et al.,
2016); 1 patient with Alu-mediated deletion of
SPG7 exons 11–13 (López et al., 2015); 3
patients with Alu microhomology-mediated
exon deletion in SPG11 (Conceição Pereira
et al., 2012)
Not known SPAST (2p)
SPG7 (16q),
SPG11 (15q)
Parkinson disease 1 patient with Alu-mediated PARK2 exon 10
deletion (Morais et al., 2016); 1 patient with
Alu-mediated DJ1 exon 1-5 deletion (Bonifati
et al., 2003)
Not known PARK2 (6q),
DJ1 (1p); for other genes
see OMIM
Alzheimer disease 1 patient with Alu-mediated PSEN1 exon 9-10
deletion (Le Guennec et al., 2017)
A-to-I editing reduced at multiple sites in
prefrontal cortex and hippocampus (see main
text; Akbarian et al., 1995; Gaisler-Salomon
et al., 2014; Khermesh et al., 2016)
APP, PSEN1 (14q), PSEN2
Epilepsy 5 patients with Alu-mediated rearrangement of
portions of ALDH7A1 (Mefford et al., 2015); 3
patients with Alu-mediated CDKL5 deletions of
various sizes (Erez et al., 2009)
Reduced and elevated A-to-I editing at various
sites (e.g. Krestel et al., 2013)
ALDH7A1 (5q),
CDKL5 (Xp)
See OMIM for further
epilepsy candiate genes
Aicardi-Goutières syndrome (AGS) ADAR1 primarily edits Alus in RNA Pol II
transcribed mRNAs, ADAR1 ko neuronal
progenitor cells exihibit spontaneous IFN
production, inhibition of mRNA translation, and
apoptosis (Chung et al., 2018)
Reduced A-to-I editing of miR376-a2 by
ADAR1 mutation frequently found in
Aicardi-Goutières syndrome (Rice et al., 2012)
ADAR1 (1q), SAMHD1,
TREX1, IFIH1
Diseases, for which human data about genetic rearrangements in association with transposable elements have been identified. For these diseases, also human data about RNA editing
were investigated and are presented. RNA editing has an important function in Aicardi-Goutrières syndrome and thus it is presented here, although transposable elements have as
yet not been causally related with its development. The very right column of the table contains major candidate genes (with chromosomal location given in brackets) that have been
implicated in the respective diseases.
activity. ADARB1 is strongly expressed in the brain (Gerber et al.,
1997; Sela et al., 2007). Another example is Alu exonization via
A-to-I editing in pre-mRNA of the human nuclear prelamin
A recognition factor (NARF) that is ubiquitously expressed
including brain. Two Alu elements in NARF intron 7 form a
dsRNA structure and undergo RNA editing, which generates a
new slice acceptor site, abolishes a stop codon, and leads to
(pseudo)exon 8 (Lev-Maor et al., 2007). However, exonization
by A-to-I editing appears to be a rather rare event (Athanasiadis
et al., 2004). It is estimated that only 4% of all transposon-
derived exons contribute to new functionality of the proteome
(Sela et al., 2007). Exonisation of Alu elements can also occur in
5
′
UTRs and generate new upstream open reading frames (Shen
et al., 2011). Alu exonization into the 3
′
UTR was described to
occur by RNA editing-mediated generation of a splice donor
site in transcripts from the GPR81 gene, a G protein-coupled
receptor with some expression in the brain (Athanasiadis et al.,
2004).
mRNAs carrying retrotransposons in their 3′UTRs appear
to be less expressed than mRNAs without retrotransposons.
In this regard, several mechanisms were discussed involving
interference with non-coding transcripts from 3′UTRs or with
other cis-regulatory elements, introduction of miRNA binding
sites, truncation of 3′UTRs by premature polyadenylation
signals in retrotransposons, and degradation in trans by
other retrotransposons (Faulkner et al., 2009). Experiments
in HeLa and HEK293 cells proposed that human mRNAs
with inverted-repeat Alu elements in their 3
′
UTR were as
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FIGURE 1 | Interaction of RNA editing and retrotransposons at the pre-mRNA level. (A) Non-LTR retrotransposons in inverted orientation in introns (hatched boxes
with red lines pointing in opposite directions) flanking an exon (e, yellow boxes) may base-pair into double-stranded RNA and form circular RNA (left) by a mechanism
called backsplicing. The residual pre-mRNA is subsequently degraded (dotted line). Deamination of an adenosine to an inosine (A→ I) by ADAR within a non-LTR
retrotransposon may prevent perfect base pairing (right) and hence formation of double-stranded cirular RNA and backsplicing. This pre-mRNA may be regularly
spliced and exported. Both mechanisms may contribute to regulation of translational efficiency. (B) A-to-I editing can activate cryptic splice sites in non-LTR
retrotransposons (hatched boxes) by deamination and creation of new splice donor (AU edited to IU = GU) and acceptor (AA edited to AI = AG) sites, resulting in
alternative splicing and exonization of non-LTR retrotransposons. This may lead to new gene functions.
likely exported to the cytoplasm as mRNAs lacking these
structures, but they were in most cases translated less efficiently.
Effects on translation were independent of the presence of
inosine – i.e., they were sequence- (and thus RNA editing)
independent - but rather dependent on the distance of
the dsRNA structure from the stop codon (Capshew et al.,
2012).
Introns and 3′UTRs may harbor multiple Alu elements
that are located in inverted orientation. Inverted Alu elements
can form intramolecular dsRNA structures and undergo A-to-
I editing (Figure 2A; Capshew et al., 2012). The function of
edited Alu elements in Pol II-transcribed mRNAs has now been
impressively demonstrated in human cells including HEK293
cells and neuronal progenitor cells (Chung et al., 2018). In
more detail, Alu elements are the primary editing target of
ADAR1 (91%) in HEK293 cells. ADAR1-edited Alu elements
were mainly found in introns (48%) and 3′ UTRs (37%). Very
few (<0.1%) of ADAR1 edits were found in open reading frames
and corresponding genes (i.e., their pre-mRNAs) edited by
ADAR1 showed no significant enrichment of any gene ontology
terms. About 5% of other TEs including L1 are editing targets
of ADAR1. Actually, ADAR1 primarily edits Alu elements in
RNA Pol II transcribed mRNAs, not Pol III transcribed Alu
transcripts. ADAR1 editing does not affect mRNA abundance.
Binding of ADAR1 to dsRNA structures within mRNAs as
well as A-to-I editing prevents inhibition of both efficient
translation of other mRNAs and cell proliferation, which are
otherwise triggered during an inflammatory interferon-γ (IFN)
response. Differentiation of ADAR1-deficient human embryonic
stem cells to neuronal progenitor cells leads to spontaneous
IFN production, activation of protein kinase R, and apoptotic
cell death. Melanoma differentiation-associated gene 5 (MDA5
or interferon-induced helicase C domain containing protein 1,
IFIH1), a soluble RNA receptor is the major dsRNA sensor
for induction of an IFN-mediated inflammatory response and
ADAR1 is a key player in preventing spontaneous MDA5
activation. MDA5 is particularly activated by the dsRNA
structures formed by inverted-repeat Alus, which are largely
present in 3′ UTR of retrotransposition-incompetent Pol II
transcripts and not by the unpaired Alu elements from
retrotranspostion-competent Pol III transcripts. Thus, deficient
A-to-I editing of inverted-repeat Alus may “breach” the immune
tolerance of MDA5 (Ahmad et al., 2018).
Finally, A-to-I editing may also affect AU-rich elements
(ARE) and micro RNA response elements (MRE) in the
3′UTR (in mice; Liddicoat et al., 2015), thereby contributing
to regulation of mRNA stability and translational efficiency
(Figure 2B).
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FIGURE 2 | Interaction of RNA editing and retrotransposons at the pre-mRNA
level. (A) Multiple non-LTR retrotransposons may be present in 3′UTR
[indicated by preceding exon (e, yellow boxes) with stop codon “UAA”] in
inverted orientation (lines in hatched boxes point in opposite directions). They
may form perfectly matched double-stranded RNA structures (middle graph).
Inverted-retrotransposon double-stranded RNA structures may also undergo
A-to-I editing by ADAR, resulting in loop formation within double-stranded
RNA (lower graph). The formation of partially matched double-stranded RNA
structures in the 3′UTR is implicated in escape from cytosolic immune
response. (B) AU-rich elements (ARE, gray box) and microRNA response
elements (MRE, blue box) in 3′UTRs represent binding sites for proteins and
microRNAs that can affect mRNA stability and translational efficiency. A-to-I
editing may modulate adenosines within ARE and MRE and thus indirectly
influence those mechanisms.
At the mRNA Level
Genomic Alu and L1 elements serve as templates for small non-
coding RNAs such as piRNAs and endo-siRNAs that themselves
do not affect the expression of protein-coding genes but control
and quiesce autonomous L1 and Alu RNAs (Figure 3; Saito
and Siomi, 2010). ADARs can have an effect on the level of
small non-coding RNAs. This is supported by ADAR knockouts
in Caenorhabditis elegans that notably had little influence on
the nucleotide sequence of mature miRNA, endo-siRNAs, and
piRNAs, but on the contrary changed expression levels of the
majority of small RNAs up to 40% when compared to wildtype
(Warf et al., 2012). While previous studies suggested an increase
of endo-siRNA levels in the absence of ADAR function (e.g.,
Wu et al., 2011), this study found predominantly reduced
small RNA levels in ADAR mutants (Warf et al., 2012). The
authors furthermore discussed an A-to-I editing impact on
dsRNA structures in the context of small RNA biogenesis or
an RNA editing-independent sequestration of dsRNA by ADAR
(Figure 3). Thus, normal ADAR protein abundance and A-to-I
editing may contribute to the suppression of retrotransposons;
a mechanism that remains to be shown in human differentiated
neurons and glia.
RETROTRANSPOSONS AND RNA EDITING
IN NEUROLOGICAL DISEASE
L1 and Alu elements have also been linked to disease. Several
comprehensive reviews on retrotransposons and specific disease
conditions have been published (Ostertag and Kazazian, 2001;
Chen et al., 2005; Belancio et al., 2008; Hancks and Kazazian,
2012; Kaer and Speek, 2013; Elbarbary et al., 2016; Larsen
et al., 2018). We are trying to provide here a comprehensive
synergy of mechanisms involved in the diseases with CNS
involvement associated with TEs (as listed in Table 1 and
Supplementary Table 1). The Supplementary Text provides
further detailed information.
Spinocerebellar Ataxias
Spinocerebellar ataxias are a group of neurodegenerative genetic
disorders characterized by slowly progressive incoordination of
gait and often associated with poor coordination of hands,
speech, and eye movements. Spinocerebellar ataxias can be
subdivided frequently according to other non-cerebellar features
including parkinsonism, chorea, pyramidal signs, cognitive
impairment, peripheral neuropathy, and seizures. Friedreich
ataxia is the best known and most commonly inherited form
of spinocerebellar ataxia. It can be caused by mutations or, in
98% of cases, by GAA trinucleotide-repeat expansions located
at the center of an AluSq element in intron 1 of the frataxin
(FXN) gene. Friedreich ataxia is the only known disease caused
by abnormal expansion of a GAA trinucleotide-repeat sequence.
It was suggested that GAA repeats arose by mutation or A-
to-G conversion from poly(A) tracts of Alu elements. Many
longer GAA repeats in the human genome can be found in
the 3′ poly(A) tracts of Alu elements, but it was suggested that
A-to-G conversion that led to poly-GAA repeats in Friedreich
ataxia arose in the central linker region of Alu elements (Clark
et al., 2004). Beyond GAA repeats, Alu elements were in
general described to be a source for microsatellites (Arcot et al.,
1995). Expansion of trinucleotide repeats was proposed to have
arisen in Friedreich ataxia rather by in-tandem duplication
up to a certain repeat length (Clark et al., 2004; Monticelli
et al., 2004). From a certain repeat length onwards, genetic
instability was proposed to contribute to additional repeat
expansion, which is known in Neurology as anticipation. GAA
repeat expansions affect pre-mRNA processing by inducing
the accumulation of upstream splicing intermediates (Baralle
et al., 2008). No interaction of RNA editing with these
genetic rearrangements in Friedreich ataxia has been reported
(Table 1).
Ataxia Teleangiectasia
Ataxia teleangiectasia is a variant spinocerebellar ataxia
associated with immunodeficiency, blood vessel dilatation,
hypogonadism, premature aging, genomic instability, radiation
sensitivity, and cancer predisoposition. It can be caused
by over 400 mutations (see Online Mendelian Inheritance
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FIGURE 3 | Interaction of RNA editing and retrotransposons at the mRNA level. Retrotransposons (brown boxes) may be transcribed in sense and antisense direction
(indicated by promoter symbols pointing in opposite directions), form double-stranded RNA (dsRNA) precursors (brown and green arrows) that are processed by Dicer
into endo short interference RNAs (endo-siRNA). Endo-siRNAs (here indicated as short green lines) are loaded onto AGO2 proteins, may detect further single-stranded
retrotransposons transcribed from other locations (middle brown brown box) and target them for degradation. Thus, the siRNA pathway contributes to retrotransposon
silencing. Levels of endo-siRNA can be affected by ADAR and/or A-to-I editing, with an increase or decrease (indicated by “+/–“) of small RNA upon loss of ADAR.
in Man, OMIM; www.omim.org) in the ATM gene. ATM
protein is a member of the phosphatidylinositol 3-kinase
family that respond to DNA damage by phosphorylating key
substrates involved in DNA repair and/or cell cycle control.
Neurological manifestiations typically occur with homozygous
or compound heterozygous mutations, while the cancer risk
is already increased with heterozygous mutations (OMIM).
48% of the mutations in ATM were reported to be splicing-
affecting mutations (Pastor et al., 2009). An individual with
ataxia teleangiectasia was compound heterozygous for a c.2250
G-to-A splicing mutation and a 4 nt deletion in ATM intron
20, which were both considered to be causal (Pagani et al.,
2002). The 4-base pair (bp) deletion disrupted an intronic
splicing processing element, leading to activation of both an
adjacent cryptic splice site and a cryptic exon. The splicing
intermediate was only further processed, i.e., the cryptic exon
was only included in the mRNA, if particular splicing factors
bound in trans to a downstream intronic splicing enhancer that
was located within an antisene Alu element (Pastor et al., 2009;
Pastor and Pagani, 2011). Not only Alu elements but also L1 were
reported to be involved in Ataxia teleangiectasia. A significantly
increased L1 copy number [normalized to non-mobile repetitive
DNA sequences (SATA, HERVH, 5sRNA gene)] was found
with Taqman-based quantitative real-time PCR in postmortem
hippocampal samples from 7 Ataxia teleangiectasia patients
compared to hippocampi from deceased controls (Coufal et al.,
2011). Yet it remains unclear how the increased L1 copy number
contributed to the cause or progression of ataxia teleangiectasia
in these patients.
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative,
genetic disease of the upper and lower motor neuron in the
cerebral cortex and spinal cord. Over 20 ALS forms have
been described in association with mutations in several genes,
which can as yet only explain a minority of all the ALS
cases (Zou et al., 2016). The majority of ALS cases occur
sporadically and up to 10% are familial. ALS type 12 with
autosomal dominant or recessive inheritance can be caused
by homozygous or heterozygous mutations in the optineurin
(OPTN) gene (Maruyama et al., 2010). Two Japanese siblings
with ALS 12 were reported with homozygous OPTN exon
5 deletion. Sequencing of the breakpoint junction showed
the 5′ part to be of AluJb from intron 4 and the 3′ part
to be of AluSx from intron 5 with an overlapping 12-bp
microhomology. Alu-mediated recombination was proposed as
deletion mechanism (Maruyama et al., 2010). The identical
homozygous deletion with Alu-involvement was found in
another ALS patient from a Japanese cohort. Further 3 patients
of this cohort carried heterozygous deletions of exons 3–
5 that occurred between Alu elements in introns 2 and 5.
A fifth patient carried a heterozygous deletion between an
Alu element 86 kb upstream to exon 1 and an Alu element
in OPTN intron 4. All types of deletions were predicted to
cause null alleles and were therefore considered to be causal
(Iida et al., 2012; Table 1). One histological hallmark of ALS
are neuronal protein aggregates in the form of cytoplasmatic
inclusions that contain several ubiquitinated proteins including
TDP-43. TDP-43 is a predominantly nuclear RNA/DNA-binding
protein with functions in RNA processing and metabolism,
including RNA transcription, splicing, transport, and stability.
Hypoediting of the glutamine/arginine (Q/R) site of -amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor
subunit GRIA2 with increased intracellular Ca2+ influx was
proposed to activate the Ca2+-dependent cysteine protease
calpain, resulting in cleavage of TDP-43 and thereby contributing
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to cytoplasmic TDP-43-positive inclusions (Yamashita et al.,
2017). It is an ongoing discussion whether cytoplasmic
inclusions are beneficial or toxic to neurons. Beyond protein
aggregates, neuronal excitotoxicity has been implicated in ALS.
One mechanism of neuronal hyperexcitability was shown to
be increased Ca2+ influx through deficiently edited GRIA2-
containing AMPA receptors (by ADAR2) that contributed to
the death of spinal motor neurons (Kawahara et al., 2004;
Table 1).
Frontotemporal Dementia
Frontotemporal dementia (FTD) is one of the most frequent
neurodegenerative dementias (besides Alzheimer disease) and
can clinically be subdivided into behavioral variant FTD (e.g.,
change of personality, hyperorality, emotional lability), primary
progressive aphasia (non-fluent speech, paraphasia, errors in
syntax), and semantic variant dementia (loss of knowledge about
function of objects, agnosia). Additional clinical symptoms can
include a dysexecutive syndrome, urine incontinence, sometimes
an extrapyramidal syndrome or pyramidal syndrome (signs of
first and second motor neuron, i.e., symptoms of ALS). Most
patients with FTD have intracellular inclusion bodies. Clinical
cases are further classified according to neuro/histopathological
criteria in FTD with inclusion bodies lacking histological
characteristics; FTD with Tau-positive inclusion bodies, TDP-
43 positive inclusion bodies, fused-in-sarcoma (FUS) or SOD-
positive inclusion bodies, and others. The majority of cases
carries TDP-43- and to a lesser extent Tau-positive inclusion
bodies. Prevalent genes implicated in FTD are MAPT, PSEN1,
GRN, TARDBP. Mutations in OPTN are rarely associated with
FTD. Recently, a FTD patient with a primary progressive aphasia
phenotype was identified, who carried a compound heterozygous
genetic rearrangement consisting of a non-sense mutation in the
TBK1 gene and a deletion spanning OPTN exons 13–15. The
breakpoint junction showed a microhomology domain of 25 bp.
Recombination occurred between sequences contained in introns
12 and 15 (Pottier et al., 2015). Although not explicitly stated,
this type of deletion is reminiscent of non-homologous end-
joining or microhomology-mediated end-joining possibly with
Alu involvement, particularly as OPTN was described to contain
38 Alu repeats (Iida et al., 2012). It would be worthwile to re-
analyze the sequence data of Pottier et al. regarding the question
whether the breakpoints occurred in putative Alu elements.
The genetic rearrangement was proposed to be causal, because
strongly reduced mRNA and protein expression were found in
the brain of this patient (Pottier et al., 2015). The observation
of OPTN being a candidate gene for both ALS and FTD
underlines previous observations that ALS and FTD are part of
a clinical, histological, and genetic disease spectrum (Neumann
et al., 2006). There is also the entity ALS- FTD that combines
symptoms of both diseases and is frequently associated with
mutations in the C9ORF72 gene. Intronic hexa-nucleotide repeat
expansions in C9ORF72 cause poly glycine-arginine aggregations
that can be found in cytoplasmic inclusions, often together with
TDP-43. ALS and FTD are subsumed into the group of TDP-
43 spectrum disorders. Increased transcript levels of AluYK12
elements have been found in frontal cortex of deceased patients
with ALS-FTD compared to cortex from healthy deceased
controls, suggesting increased retrotransposon pathology in
ALS-FTD cases (Prudencio et al., 2017). Retrotransposon and
transposon transcripts may also interact with TDP-43. Mining of
a series of deep sequencing datasets of protein-RNA interactions
(CLIP-seq) from human healthy and FTLD (frontotemporal
lobar degeneration, the neuropathological term of FTD) brain
tissues uncovered extensive binding of TDP-43 to TE transcripts
(non-LTR, LTR, DNA elements; Li et al., 2012). The association
between TDP-43 and TE-derived RNA targets was significantly
reduced in patients with FTLD compared to healthy subjects.
Yet the reason remained unclear particularly whether the
reduced binding of TE transcripts in FTLD tissue was due to
immunoprecipitation of smaller amounts of TDP-43 protein
bound to TE RNA because residual TDP-43 was lumped
together in cytoplasmic inclusions. Simultaneously, RNA-seq
experiments in mice with TDP-43 pathology (one mouse strain
with transgenic overexpression of human TDP-43; secondmouse
strain with antisense oligonucleotide-mediated depletion of
TDP-43 in striatum that is a part of basal ganglia) both revealed
significant elevation of TE-derived transcripts with a striking
concordance to those TE RNAs that were identified as RNA
targets of TDP-43 in CLIP-seq experiments of mice (Li et al.,
2012). The hypothesis was brought forward that TDP-43 acts as
a scavenger for TE-derived RNAs and elevated expression of TE-
derived transcripts would occur, if TDP-43 was dysfunctional or
misrepresented in the nucleus, (Li et al., 2012; Erwin et al., 2014;
Figure 4). It remained to be clarified how elevated expression of
TE RNA resulted in neurodegenerative disease and whether an
increased number of somatic retrotransposition events occurred:
in this regard, genomic instability, DNA damage, and toxic
effects were discussed (Li et al., 2012). In subsequent work
by the same group, it was shown that TDP-43 interfered with
siRNA-mediated silencing of TE transcripts and that elevated
expression of the LTR-retrotransposon gypsy (most active TE
in Drosophila) was associated with enhanced TUNEL staining,
taken together as evidence for increased apoptosis. In addition,
experiments demonstrated that these mechanisms contributed
to the ALS-phenotype in a Drosophila (Krug et al., 2017). It
remains to be shown in humans, if, and if so how, increased
levels of TE transcripts may contribute to ALS and FTD. RNA
editing has not yet been associated with FTD or ALS-FTD,
although ALS was associated with impaired editing, and FTD
as well as ALS share a common pathophysiological spectrum
(Table 1).
Hereditary Spastic Paraplegias
Hereditary spastic paraplegias are characterized by progessive
spasticity and weakness of the legs. Autosomal dominant spastic
paraplegia-4 (SPG4) with relatively pure lower limb spastic
paraplegia is caused by heterozygous mutations in the SPAST
gene. Three new SPG4 patients were described who carried
heterozygous deletions of various sizes, all including SPAST
exon 17. All breakpoints occurred in Alu elements, in only
one patient in Alu elements of the same family. All deletions
displayed a microhomology at the breakpoint junction. In
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FIGURE 4 | Transactive response DNA-binding protein (TDP-43 or TARDBP) may bind to single-stranded retrotransposons or to retrotransposons embedded in
pre-mRNA and may regulate TE abundance or affect A-to-I editing. Normally, TDP-43 is proposed to act as a scavenger of TE-derived transcripts and regulates TE
abundance. When TDP-43 function becomes comprised, as in certain neurodegenerative diseases with depletion of TDP-43 from the nucleus and aggreation in the
neuronal cytoplasm, TEs become overexpressed (shown left-hand; Krug et al., 2017). Depicted right-hand, TDP-43 can also bind to retrotransposons contained in
pre-mRNA and it was proposed that TDP-43 limits the extent of ADAR-mediated A-to-I editing in intronic inverted repeat dsRNA structures. A-to-I editing increases if
nuclear TDP-43 is depleted. The bidirectional arrow questions whether the interaction is reciprocal and whether altered A-to-I editing may also lead to compromised
binding of TDP-43 to pre-mRNA with loss of nuclear TDP-43 predominance, translocation to the cytoplasm, and aggregation. Yellow parts represent exons (e).
one patient, insertion of an Alu fragment was additionally
found at the breakpoint junction. A microhomology-mediated
deletion was proposed as the mechanism of exon loss. It was
argued against non-allelic homologous recombination, because
breakpoint Alus were of different families in 2 patients and
sequence identity was <90% (Boone et al., 2011). Furthermore,
60 SPG4 patients were studied in leukocyte DNA for genetic
rearrangements in SPAST. Some patients of this large study were
published previously. Of the 54 CNVs analyzed, 70% appeared
to have been mediated by an Alu-based mechanism. The Alu-
mediated CNVs were in principle consistent with homologous
recombination between non-allelic Alus. Based on short length
(<300 bp) and low percent sequence identity (<91%) of Alus,
the mechanism of Alu-Alu recombination was questioned.
Alternative rearrangementmechanisms were discussed including
microhomology-mediated DNA repair (Boone et al., 2014 and
references therein). Moreover, 2 different CNVs in the SPAST
gene of 2 separate German families were characterized. Both
were deletions of different size and location and both carried
insertions of different size at the breakpoint junction. The larger
insertion matched an AluYb8 sequence while the smaller 15-
bp insertion was in microhomology to a general Alu consensus
sequence. Therefore, a mechanism with Alu retrotransposition
(insertion) was proposed, followed by non-allelic homologous
recombination (for the deletion with the larger insertion) or
non-homologous end joining (for the deletion with the smaller
insertion) (Jahic et al., 2016). Large deletions can also be found
in the SPG7 gene that is responsible for spastic paraplegia type 7,
another form of autosomal recessive spastic paraplegia. Mother
and son of a Spanish family with spastic paraplegia type 7 carried
a complex rearrangement (the mother was homozygous and the
son heterozygous for the rearrangement), which consisted of a
deletion of SPG7 exons 11–13, with the eventual 5′ breakpoint
in an AluSq element, the 3′ breakpoint adjacent to a core chi-
like sequence (gctgg), and insertion of a 8-bp fragment from
an intermediate AluSx element at the breakpoint junction. The
sequence gctgg is contained in the chi sequence (gctggtggg)
and is also present in the 26-bp core region of some Alu
elements. López et al. suggested that recombination between
Alu elements and chi sequences can take place by formation
of intrachromosomal loops and deletion of the intervening
sequences. A microhomology-mediated deletion was proposed
as additional rearrangement mechanism, because the breakpoint
contained a 8-bp insertion (López et al., 2015). A similar picture
with Alu microhomology-mediated exon deletion was observed
in the gene SPG11 in 3 patients with autosomal recessive spastic
paraplegia type 11 (Conceição Pereira et al., 2012; Table 1).
Parkinson Disease
Parkinson disease is diagnosed by presence of the clinical trias
“rigor, tremor, and akinesia.” Dominance of one symptom
of the Parkinsonian trias, co-morbidities, age of onset, and
sporadic or familial occurence further classify this disease. Many
candidate genes have been implicated in Parkinson disease and
its variants (see OMIM). Mutations in the PARK2 gene were
made responsible for autosomal-recessive juvenile Parkinson
disease. PARK2 carries a high frequency of deletions. It was
proposed that PARK2 is located in a fragile site of the genome
(Morais et al., 2016 and references therein). 17 Portugiese
patients with autosomal-recessive juvenile Parkinson disease
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were reported with large homozygous or heterozygous PARK2
deletions. PARK2 deletions were heterogeneous in size and
location and sometimes contained an insertion fragment. 5′
and 3′ breakpoints occurred in different types of sequences: 2
Alu elements, 1 Alu and various unique sequences, 2 uniques
sequences, 1 Alu and 1 DNA transposon, 1 LINE-1 and 1
LINE-2/LTR- transposon, etc. Several deletion mechanisms were
discussed: nonallelic homologous recombination between Alu
elements, nonhomologous end joining, and microhomology-
mediated end joining. The variability in breakpoints and
rearrangements was explained by the independence of recurrent
events, which remains to be demonstrated. Only a few patients
with homozygous deletions had identical breakpoints. A subset
of these patients were cosanguinous and a founder mutation was
made responsible for identical breakpoints (Morais et al., 2016).
Mutations in the DJ1 gene are implicated in autosomal recessive
early-onset Parkinson disease (PARK7). One Dutch patient
carried a homozygous genomic deletion of DJ1 exons 1–5 with
breakpoints occuring within 16 bp of sequence (microhomology)
identical in 2 Alu elements flanking the deletion. An unequal
crossing-over (or non-allelic homologous recombination) was
the proposed genomic rearrangement mechanism (Bonifati et al.,
2003; Table 1).
Alzheimer Disease
Mutations in the Amyloid Precursor protein (APP), Presenilin
1 (PSEN1) and Presenilin 2 (PSEN2) genes and duplications of
the APP locus are the main causes of autosomal dominant early-
onsetAlzheimer’s disease. One patient with a heterozygous PSEN1
deletion of exons 9–10 was reported with breakpoints located
in a 24 bp homologous sequence in 2 different Alu elements.
A homologous Alu-mediated recombination was suggested, and
causality was inferred from in-vitro experiments (Le Guennec
et al., 2017; Table 1). Reduced A-to-I editing in Alzheimer’s
patients was found in prefrontal cortex at the GRIA2 Q/R
site (99 vs. >99.9% in controls; Akbarian et al., 1995) and in
hippocampus at various protein-recoding sites including GRIA3,
GRIA4, GRI1, KCNA1, CACNA1D (Khermesh et al., 2016), and
GRIA2 Q/R (Gaisler-Salomon et al., 2014; Table 1).
Human Epilepsy
Human epilepsy has as yet been associated with retrotransposon-
mediated genetic rearrangements only in a few cases. Five
patients have been reported with heterozygous Alu-mediated
deletions in ALDH7A1, the gene responsible for pyridoxine-
dependent epilepsy. This usually is a neonatal-onset epilepsy
with various seizure types and unresponsiveness to standard
anticonvulsants, responding only to immediate administration
of pyridoxine hydrochloride. The dependence is permanent, and
the interruption of daily pyridoxine supplementation leads to
the recurrence of seizures. It is a metabolically caused epilepsy,
because homozygous or compound heterozygous ALDH7A1
mutations lead to enzyme deficiency and perturbation of the
pipecolic acid pathway of lysine catabolism. In 2 sibelings
with pyridoxine-dependent epilepsy, ALDH7A1 exon 7 was
heterozygously deleted and breakpoints were located in Alus
of different families sharing 82% homology. A microhomology
(overlapping identical sequence from the breakpoint Alus) of
11 bp was found at the breakpoint junction. A third patient
carried a heterozygous ALDH7A1 exon 18 deletion. Breakpoints
occurred in 2 Alu elements that shared 85% homology. A 18-
bp microhomology was found at the breakpoint junction. In
2 further patients, array CGH data indicated that breakpoints
were located in intronic clusters of Alu elements. Alu-Alu
recombination was the proposed rearrangement mechanism.
Deletions were predicted to lead to a truncated protein in 3
patients and suspected to be detrimental, particularly as all
patients additionally carried compound heterozygous ALDH7A1
point mutations (Mefford et al., 2015). Early infantile epileptic
encephalopathy-2 (EIEE2) with seizure onset in the first months
of life and severe developmental delay has been associated
with mutations in CDKL5. Three EIEE2 patients with variable
deletions of CDKL5 exons 1–4 were reported. In 2 patients the
breakpoints were located in Alu elements of different families,
and in one patient deletion between an AluJb and a unique
sequence occurred. The breakpoint junctions of the Alu-Alu
deletions contained perfect microhomology sequences (identical
sequences 7–15-bp long). Microhomology-Mediated Break-
Induced Replication/Fork Stalling and Template Switching was
suggested as deletion mechanism (Erez et al., 2009). The human
CHNRA6 gene was shown to contain 2 Alus in tandem in
its 5′ regulatory sequences that negatively controlled CHRNA6
expression irrespectively of their dual or singulary presence and
orientation (Ebihara et al., 2002). A-to-I editing alterations in
humans with epilepsy have been reported (e.g., Krestel et al.,
2013 and references therein), but more recent studies with an
update on newly discovered protein-recoding sites, sites edited
to low extent in combination with functional studies, or non-
coding editing sites could not be identified in our data base
search (but see Meier et al., 2016). While the function of RNA
editing has to be analyzed in somatic tissue, i.e., brain, and in case
of (mesial) temporal lobe epilepsy (TLE) in hippocampus, the
studies regarding the contribution of retrotransposons to human
epilepsy have as yet been performed in DNA from blood only.
However, we are currently undertaking a study to analyze the
contribution of retrotransposons and RNA editing to somatic
mosaicism (see McConnell et al., 2013) in human hippocampi of
TLE patients to identify additional genetic factors in a disease that
could as yet be traced back to only few genetic variants in DNA
from blood.
Aicardi-Goutières Syndrome
Aicardi-Goutières syndrome is an early onset autoinflammatory
disorder with spontaneous IFN production in the absence of
virus infection (aseptic), particularly affecting the brain (cerebral
atrophy, seizures, poor feeding, jitteriness, cerebral calcifications,
white matter abnormalities) and skin. Mutations in ADAR1
have been identified as one cause, although the mechanism(s)
leading to the neurological manifestations remained unclear
(Rice et al., 2012). ADAR1 deficiency has now been shown to
cause spontaneous IFN-gamma production in human neuronal
progenitor cells and apoptotic cell death (Chung et al., 2018).
Given the fact that ADAR1 primarily edits Alus embedded in
mRNAs, Aicardi-Goutières syndrome may be the prime example
of an autoinflammatory disorder (with deficiently edited Alus
Frontiers in Molecular Neuroscience | www.frontiersin.org 10 May 2018 | Volume 11 | Article 163
Krestel and Meier Genomic Rearrangement and Neuroinflammation
resulting in an aseptic neuroinflammatory response), in which
A-to-I editing of retrotransposons has gone awry.
TDP-43 SPECTRUM DISORDERS,
RETROTRANSPOSONS, A-TO-I EDITING,
AND INFLAMMATION
Several recent results argue in favor of a cooperation of TDP-
43 with ADARs. First, both are predominantly nuclear proteins,
even if TDP-43 can also be encountered to a small percentage
in the cytoplasmic fraction and here particularly bound to the
3′UTR of mRNAs. Second, both proteins bind to pre-mRNA.
This is known for ADARs, and shown with predominant binding
of TDP-43 to introns in the nuclear fraction of post-mortem
human neocortex samples from 3 cognitively normal (healthy)
and 3 patients with sporadic FTLD (Tollervey et al., 2011). Third,
knockdown of TDP-43 inmouse lowers expression of the ADAR2
transcript (andmany other transcripts; Polymenidou et al., 2011).
Thus, a deficit in RNA editing secondary to altered TDP-43
levels is conceivable. Accordingly, hypoediting of GRIA2/Gria2
as the main substrate of ADAR2 in the findings of ALS
patients and mouse models could be both the triggering event
for TDP-43 cleavage with subsequent cytoplasmic aggregation
(as mentioned in chapter 4; Yamashita et al., 2017) and the
consequence of reduced ADAR2 expression due to nuclear TDP-
43 depletion and cytoplasmic aggregation. The hypothesis of a
secondary hypoediting of GRIA2/Gria2 seems to be supported
by lowered ADAR2 levels in spinal cord motor neurons of ALS
patients (Hideyama et al., 2012). A fourth piece of evidence
for the relationship between ADAR-mediated A-to-I editing and
altered TDP-43 levels originates from knockdown experiments
in Caenorhabditis elegans, HeLa cells, and M17 neuroblastoma
cells. siRNA knockdowns of the Caenorhabditis elegans ortholog
TDP-1 and TDP-43 in HeLa and M17 cells not only showed an
increase in transcripts from the human endogenous retrovirus
of the K subfamily (HERVK), but also an increase of A-to-I
edits in introns (in inverted repeats), and in 3′UTRs of mRNAs
(Saldi et al., 2014). It can be interesting to investigate whether
TDP-43 binds to, or close to, inverted intronic Alu elements
and cooperates with ADARs to regulate translational efficiency,
e.g., by modulating A-to-I editing-mediated backsplicing or
alternative splicing including Alu exonization (Figure 4). The
same may apply for TDP-43 binding to 3′UTRs and A-to-I
editing of dsRNA structures in 3′UTRs. It is therefore tempting to
speculate if reciprocal interaction between TDP-43 and ADARs
also exists in the sense that primarily dysregulated A-to-I editing
affects TDP-43 binding (Figure 4).
Another possibly interesting interaction exists between
neurodegenerative diseases/TDP-43 spectrum disorders and
neuroinflammation. Neuroinflammation was proposed to be
one causative factor for the disease or at least for disease
progression e.g., of Parkinson’s or Alzheimer’s disease (Whitton,
2007; Heneka et al., 2015). Current pathophysiological opinion is
that e.g., Amyloid beta (in Alzheimer’s) and alpha synuclein (in
synucleinopathies including Parkinson’s), together with sensing
of ATP and DNA from damaged neurons via purinergic P2X7
receptors, activate microglia that are key cellular components of
the neuroimmune system. Activated microglia in turn induce
via NF-κB and other transcription factors the production
of inflammatory cytokines and reactive oxygen species that
progressively harm cholinergic or dopaminergic neurons,
respectively (Glass et al., 2010). A new avenue in pathogenesis
may arise from the potential direct activation of microglia by
dysregulated TDP-43. Microglia have a “sensome” that refers to
an unique grouping of transcripts coding for microglia receptors
and transmembrane proteins used for sensing endogenous
ligands and microbes. The sensome is more expressed in
microglia compared to neurons and is supposed to signal
proinflammatory microglial activation. The murine sensome
with its top 100 transcripts is provided in Hickman et al. (2013).
Of these 100 transcripts, 27 were significantly upregulated upon
TDP-43 depletion following antisense nucleotide injection in
striatum of normal adult mice. These upregulated transcripts
were P2ry13, Tgfbr2, Tnfrsf1b, C3ar1, Ccrl2, C5ar1, Fcgr3,
Fcer1g, Fcgr2b, Fcgr1, Ly86, Cd68, Trem2, Cd180, Tlr2, Tlr7,
Cxcl16, Cd48, Cd74, Itgb5, Lgals9, Cd52, Icam1, Cd84, Ptprc,
Cd22, Cd53). One transcript was significantly downregulated
(Siglech) and the remaining 72% of transcripts had unchanged
expression (Supplementary Information in Polymenidou et al.,
2011). These results suggest microglial activation upon TDP-
43 dysregulation (i.e., nuclear TDP-43 depletion). To test the
hypothesis of transcriptional upregulation of the microglial
sensome by nuclear TDP-43 depletion in patients, RNA-seq data
are necessary that are not yet available from FTLD brains of
patients, at least not in the Sequence Read Archive (SRA) of
NCBI. The CLIP-seq data from Tollervey et al. cannot be used
for this purpose as they had analyzed particular protein-RNA
interactions (Tollervey et al., 2011). In the SRA, total RNA-
seq data are however available of motor neuron populations
isolated from sporadic ALS cases and controls (SRA accession
SRP067645, project 306659) as well as from homogenized
cervical spine sections of sporadic ALS and healthy control
subjects (SRA accession SRP064478, project 297335). Thus, using
these data it should be possible to evaluate the “upregulated TDP-
43-microglia transcript” hypothesis, provided that the sensitivity
of RNA-seq is high enough (i.e., enough reads have been
generated). Otherwise, human microglia have to be isolated from
post-mortem tissues (which is possible by FACS; e.g. Galatro
et al., 2017), their RNA expression profiles determined and
compared with murine data (Polymenidou et al., 2011).
IMMUNOGENICITY OF ENDOGENOUS
MRNAS WITH IMPROPERLY EDITED
INVERTED RETROTRANSPOSONS AS
ADDITIONAL CAUSE FOR INFLAMMATION
IN NEUROLOGICAL DISEASE?
It is known for more than 50 years that the presence of foreign
dsRNA in the cytoplasm of mammalian cells induces expression
of interferon and thus activates an immune response (Lampson
et al., 1967; Gantier and Williams, 2007). On the other hand, it
is also known that cells produce large amounts of endogenous
dsRNA. It was shown recently in human cells that mRNAs with
embedded dsRNA structures are exported into the cytoplasm,
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that deficient A-to-I editing does not affect their cytosolic
abundance, and that the purpose of A-to-I editing by ADAR1
rather seems to interfere with perfect matching of non-coding
dsRNA and introduce formation of loop structures in order to
avoid recognition by cytosolic soluble sensors of the interferon-
mediated immune response such as MDA5; see above, chapter
3.2 (Liddicoat et al., 2015; George et al., 2016; Ahmad et al., 2018;
Chung et al., 2018).
An association of hypoedited ds-Alu structures in 3′UTRs of
mRNAs with neuroinflammation in TDP-43 spectrum disorders,
neurodegenerative diseases in general (such as spinocerebellar
ataxia, hereditary spastic paraplegia), and epilepsy has not
been explored yet. The RNA editing status in neurological
diseases has usually only been selectively examined with a
focus on protein-recoding sites while data from sites in non-
coding transcripts are largely missing (Table 1, Supplementary
Text, Supplementary Table 1). Therefore, we can currently only
speculate, which changes RNA editing undergoes at non-coding
sites. Several neurological diseases (Huntington disease Akbarian
et al., 1995; Alzheimer disease; Akbarian et al., 1995; Gaisler-
Salomon et al., 2014; Khermesh et al., 2016; ALS; Kawahara
et al., 2004) and epilepsy (e.g., Krestel et al., 2013), respond with
both reduced and elevated A-to-I editing to their disease states
and progression, with a tendency that reduced A-to-I editing
levels at protein-recoding sites, compared to controls if they exist,
prevail (for a recent review see Meier et al., 2016). If reduced
editing of non-coding sites were also identified in inverted-repeat
ds-Alu elements in 3′UTR of mRNAs this would represent an
alternative hypothesis for neuroinflammation in these diseases.
That is, because absence of ADAR1-mediated RNA modification
would result in a structural loss of loops and gain of more
perfectly matched dsRNA structures, which could be recognized
by MDA5 that in turn would activate an immune response
(Figure 5).
A relatively new field of autoimmune encephalitides now
offers potential cure for some patients who may previously have
been diagnosed with a psychiatric illness but also with epilepsy
of unknown origin. Many of these acute-onset autoimmune
encephalitides can now be diagnosed by detection of antibodies
against glutamate receptors, GABA receptors, potassium
channels or proteins of synaptic boutons such as LGI-1 and
CASPR2, and others in blood or cerebrospinal fluid of patients
(see e.g., Graus et al., 2016). Still, not all patients suspected to
suffer from autoimmune encephalitis can be diagnosed with a
particular causative antibody. These patients are thus probatorily
treated with immune-modulatory drugs. If they respond to
treatment (frequently only a few patients with partial response),
their disease is usually termed steroid-responsive which covers
all sorts of (mostly unknown) etiologies. Identification of
a subset of mRNAs with deficiently edited 3′UTR dsRNA
structures in the pool of >5% of mRNAs that are assumed
to carry inverted-repeat ds-Alu structures in their 3′UTRs
(Capshew et al., 2012) could reveal new pro-inflammatory
causes, particularly in those steroid-responsive encephalopathies
in which no causative autoimmune antibodies can as yet be
identified.
CONCLUSIONS AND PERSPECTIVES
Transposable Elements in the Generation
of Genetic Rearrangements
In most if not all neurological diseases cited in this review
(Table 1, Supplementary Text, Supplementary Table 1), TEs
were involved in genetic rearrangement and the association
between rearrangement and disease cause was frequently
convincing. RNA editing alterations in contrast have either not
been investigated in many diseases or have almost exclusively
been reported at protein-recoding sites. The few RNA editing
events at protein recoding sites appeared seemingly detached
from previous reports about the overwhelming majority of
edits in non-coding Alu sequences, and from the genetic
rearrangements in the diseases discussed here. In addition,
A-to-I editing has as yet no function in the mechanisms
that were proposed to cause these genetic rearrangements.
These mechanisms briefly are non-allelic homologous
recombination (NAHR), non-homologous end-joining (NHEJ),
microhomology-mediated end-joining (MMEJ), and replication-
based mechanisms that predominantly occur in the S phase
of the cell cycle and which are fork stalling and template
switching (FoSTeS) and microhomology-mediated break-
induced replication (MMBIR) (Zhang et al., 2009; Ottaviani
et al., 2014). The mechanism of Alu retrotransposition-mediated
deletion adds to the repertoire of genetic rearrangements,
particularly as Alu insertions do not have to occur at typical AT-
rich L1 endonuclease cleavage sites but can also use single-strand
genomic breaks and integrate without the target site duplications
at its ends that are otherwise typical for canonical Alu insertions
(Callinan et al., 2005). The genetic rearrangements of the diseases
cited in this review carry sequence signatures of one or several
of the above-mentioned mechanisms. The difficulties in defining
the rearrangement mechanism were frequently mentioned in
the publications describing them. Indeed, some rearrangements
were proposed to have taken place by NAHR, but retrospectively
carry sequence signatures that would also qualify them for
NHEJ or Alu retrotransposition-mediated deletion (e.g., Kutsche
et al., 2002; Bonifati et al., 2003; in the Supplementary Text).
Many questions remain: the most important of them are how
somatic rearrangements in the brain look like as all copy number
variants in the neurological diseases described here have been
exclusively described in DNA samples from EDTA-blood. Were
so far only “tips of the icebergs” discovered by DNA analysis
of blood samples - do neuronal genetic rearrangements look
substantially different and contribute in as yet unexplored ways
to disease pathogenesis - are genetic rearrangements ongoing
in postmitotic neurons and which mechanisms apply? NAHR,
NHEJ, MMEJ are the preferred methods of repair during the
G1 and G2 phases of the cell cycle, while FoSTeS and MMBIR
preferentially occur during the S phase. Which mechanisms do
repair genomic deletions in differentiated neurons in the G0
phase, particularly those with microhomology or Alu fragment
insertion at the breakpoint junctions and how are they initiated?
In fact, increased expression of non-coding single-stranded
transcripts and augmented genomic integration of Alu and L1
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FIGURE 5 | Possible mechanisms contributing to autoimmune encephalitides. In the center of the figure, an axial, T2-weighed magnetic resonance imaging section of
a human brain is shown. The hyperintense (whitish “S”-shaped) structures represent inflammed, swollen hippocampi that are frequently affected in so-called
autoimmune (limbic) encephalitis. Several forms are mainly B-lymphocyte- (B cell-) mediated with identification of a causative antibody (green). T-lymphocytes (T cell)
and activated microglia (M1) may also contribute to neuroinflammation. Edited dsRNA in the 3′UTR of mRNAs may not be perfectly base-paired and thus contains
loop structures that are not recognized by melanoma differentiation-associated gene 5 (MDA5), a cytoplasmic, soluble viral RNA receptor that activates a type I
interferon mediated immune response (upper left graph). MDA5 consists of a N-terminal caspase recruitment domain (orange) a helicase domain (gray), and a
C-terminal domain (blue; after Berke and Modis, 2012). Hypoedited and thus perfectly base-paired double-stranded RNA binds to the helicase and C-terminal
domains and induces changes in the conformation and oligomerization of MDA5 that triggers an inflammatory response. An equivalent neuroinflammatory mechanism
remains to be investigated in encephalitis patients (indicated by red question mark), but also in patients with neurodegenerative diseases, epilepsy, and other diseases
where neuroinflammation is an important co-factor.
elements have been reported in several neurological diseases
(e.g., in ALS-FTD, Prudencio et al., 2017; or Rett syndrome,
Muotri et al., 2010, see Supplementary Text), and we propose
that Alu (and possibly L1) retrotransposition-mediated deletion
may be an accentuated mechanism for somatic genomic
rearrangement. Accordingly, it may rather be the RNA-binding
function of ADAR1 that offers some protection from Alu (and
possibly L1) retrotransposition-mediated rearrangements than
ADAR’s enzymatic deamination function. There is evidence that
Alu and LINE-1 retrotransposition is suppressed by ADAR1
through an RNA editing-independent mechanism that involves
binding the L1/Alu-RNP complex (Orecchini et al., 2017b and
references therein). Trapping of TE transcripts might also occur
by other proteins. Actually, extensive binding of TDP-43 to
non-coding single-stranded TE transcripts in brain tissue from
FTD patients and in a disease mouse model was proposed to
have a scavenging function (Li et al., 2012); see also Figure 6. If
such a function turned out to be correct, it should be possible to
detect TE transcripts in TDP-43 positive inclusions of classical
TDP-43 spectrum disorders (which has not been reported until
now).
A-to-I Editing of Retrotransposons
Embedded in Pol II Generated mRNAS
A-to-I editing of intronic Alu elements can contribute to
the generation of circular RNAs and thus to the regulation
of translational efficiency as well as to the creation of
alternative splice donor or acceptor sites and thus, via alternative
splicing and exonisation, to new function (see chapter 3.2).
Alu elements (without obvious editing) in the 5′UTR can
regulate gene expression (see example with CHNRA6 in chapter
4). The major function of ADAR1-mediated A-to-I editing
of inverted-repeat Alus (and perhaps L1; Orecchini et al.,
2017a and references therein) in the 3′UTR seems to be
suppression (or regulation) of the endogenous IFN-mediated
immune response (George et al., 2016; Mu et al., 2016;
Ahmad et al., 2018; Chung et al., 2018). Thus, endogenous
dsRNA structures emerge as a new factor in inflammation
and in the context of this manuscript in neuroinflammation.
The neuroimmune system is composed primarily of glial
cells including astrocytes, microglia, oligodendrocytes, and
mast cells originating from the hematopoietic lineage. Cellular
components of the neuroimmune system contain cytosolic
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FIGURE 6 | Hypothesis how transposable element-mediated genetic rearrangement could be counteracted by protein-RNA binding. Retrotransposon transcription
from internal promoters can be activated by heat shock and disease as was for example reported in patients with amyotrophic lateral sclerosis-frontotemporal
dementia (Prudencio et al., 2017; chapter 4). Activated TE transcription is indicated by detaching histone (beige oval), active promoter symbol, and multiple
single-stranded mRNAs (brown lines with poly(A) tail). Single-stranded TE transcripts can be bound by TDP-43 or exported to the cytoplasm where they bind to
ribonucleoprotein (RNP) particles depicted here as single-stranded RNA wrapped around RNP. Retrotransposon-RNP particles can be bound by ADAR or
retransported into the nucleus where reverse-transcribed retrotransposons can integrate into the genome(hatched brown boxes). Excess TE transcripts could be
scavanged by nuclear TDP-43 protein and cytosolic ADAR1 and thus may counteract TE mediated genetic rearrangement in neurological disease.
protein complexes, termed inflammasomes, that sense infectious
or other host stimuli and initiate inflammatory responses
through caspase activation (Mamik and Power, 2017). The
activated inflammasomes e.g., in microglia are an emerging
field with continuous identification of new triggers (e.g., Johann
et al., 2015; Mamik and Power, 2017; TDP-43 as inflammasome
trigger; Heneka et al., 2013; Zhao et al., 2015). Although
hypoedited endogenous dsRNA structures are as yet not in the
focus of attention as inflammatory trigger, more research in
this line could answer several questions raised in this review,
particularly as neuroinflammation is such an important co-factor
in neurodegenerative diseases (Alzheimer’s, Parkinson’s, FTD,
ALS etc.), epilepsy (e.g., Vezzani et al., 2011, 2013), and other
diseases.
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Supplementary Table 1 | Inborn errors of metabolism and neurodevelopmental
disorders. Diseases with neurological involvement as well as 2 types of
spinocerebellar ataxia, spinal muscular atrophy, glioma, and schizophrenia are
presented, for which human data about genetic rearrangements in association
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the table contains major candidate genes (with chromosomal location given in
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